Skip Navigation

European Heart Journal 2001 22(16):1476-1484; doi:10.1053/euhj.2000.2543
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zwart-van Rijkom, J.E.F
Right arrow Articles by van Hout, B.A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zwart-van Rijkom, J.E.F
Right arrow Articles by van Hout, B.A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Cost-efficacy in interventional cardiology; results from the EPISTENT study

J.E.F Zwart-van Rijkoma,b,f1 and B.A van Houtc

a Erasmus University, Institute for Medical Technology Assessment, Rotterdam, The Netherlands
b Utrecht University, Department of Pharmaco-epidemiology and Pharmacotherapy, Utrecht, The Netherlands
c University Medical Center Utrecht, Julius Center for General Practice and Patient-oriented Research, Utrecht, The Netherlands

revised November 13, 2000; accepted November 22, 2000

Abstract

Aims The EPISTENT study has demonstrated that the combined use of abciximab and stenting as an adjunct to PTCA leads to increased event-free survival compared to either using abciximab or stenting alone. However, this combined strategy may be costly and the additional costs have to be weighted against the additional effects.

Method and Results The 6-months efficacy data from the EPISTENT study are combined with Dutch estimates of unit costs. Adding a stent to a procedure with abciximab further decreases the number of revascularizations at an extra cost of Euros12000 (95% upper limit (u.l.) Euros31000) per additional major adverse cardiac event-free survivor. Adding abciximab to a stenting procedure decreases the incidence of myocardial infarctions at an extra cost of Euros13000 (95% u.l. Euros27000) per additional myocardial infarction-free survivor. In the subgroup of diabetics, adding abciximab improves revascularization rates as well, resulting in a cost-efficacy rate of Euros2000 (95% u.l. Euros25000) per additional MACE-free survivor, with uncertainty regions indicating potential costs savings.

Conclusion The combination of stenting and abciximab costs about Euros13000 to avoid one event after PTCA. In diabetic patients the strategy may be cost-saving.

Key Words: Cost-effectiveness, platelet aggregation inhibitors, stents, clinical trials, diabetes mellitus

f1 Correspondence: Jeannette E. F. Zwart-van Rijkom, Department of Pharmaco-epidemiology and Pharmacotherapy, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
S. Elezi, A. Dibra, U. Folkerts, J. Mehilli, S. Heigl, A. Schomig, and A. Kastrati
Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 262 - 267.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. A Crouch, J. M Nappi, and K. I Cheang
Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome
Ann. Pharmacother., June 1, 2003; 37(6): 860 - 875.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
W.S. Weintraub
Economics of coronary stenting and GPIIb/IIIa blockade
Eur. Heart J., August 2, 2001; 22(16): 1366 - 1368.
[PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.